A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study

Киселев, В. И.; Ashrafyan, L. A.; Muyzhnek, Ekaterina; Герфанова, Е. В.; Антонова, И. Б.; Алешикова, О. И.; Sarkar, Fazlul H.

doi:10.1186/s12885-018-4792-9

Cited by 36 publications

(26 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, recent study has suggested the use of EGCG in combination with indole-3-carbinol for better treatment outcomes in advanced ovarian cancer patients (Kiselev et al, 2018). Currently, a randomized, early phase 1 trial is ongoing to evaluate the chemopreventive effects of Teavigo™ (highly purified and refined green tea extract providing 94% EGCG) (450 mg/PO/day) in colorectal cancer (CRC) patients with curative resections (NCT03072992).…”

Section: Phytochemicals Evaluated In Clinical Trialsmentioning

confidence: 99%

Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice

et al. 2020

View full text Add to dashboard Cite

Cancer is a severe health problem that continues to be a leading cause of death worldwide. Increasing knowledge of the molecular mechanisms underlying cancer progression has led to the development of a vast number of anticancer drugs. However, the use of chemically synthesized drugs has not significantly improved the overall survival rate over the past few decades. As a result, new strategies and novel chemoprevention agents are needed to complement current cancer therapies to improve efficiency. Naturally occurring compounds from plants known as phytochemicals, serve as vital resources for novel drugs and are also sources for cancer therapy. Some typical examples include taxol analogs, vinca alkaloids such as vincristine, vinblastine, and podophyllotoxin analogs. These phytochemicals often act via regulating molecular pathways which are implicated in growth and progression of cancer. The specific mechanisms include increasing antioxidant status, carcinogen inactivation, inhibiting proliferation, induction of cell cycle arrest and apoptosis; and regulation of the immune system. The primary objective of this review is to describe what we know to date of the active compounds in the natural products, along with their pharmacologic action and molecular or specific targets. Recent trends and gaps in phytochemical based anticancer drug discovery are also explored. The authors wish to expand the phytochemical research area not only for their scientific soundness but also for their potential druggability. Hence, the emphasis is given to information about anticancer phytochemicals which are evaluated at preclinical and clinical level.

show abstract

Section: Phytochemicals Evaluated In Clinical Trialsmentioning

confidence: 99%

Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Finally, we proceeded with the analysis of the articles studying long-term interventions (Table S3). In these works, we found various publications on different types of cancers: prostate [48,49], breast [37], ovarian [50], and pancreas (pilot [51] and development [52]), and one work on type 2 diabetes mellitus [35] and a letter to the editor [38] as a result of this study.…”

Section: Long-term Studiesmentioning

confidence: 81%

“…The works of Thomson et al [37] on breast cancer and Kiselev et al [50] on ovarian cancer were studies with the highest number of participants and the longest periods of evaluation. Thomson et al [37] studied the effects of diindolylmethane (DIM) + tamoxifen administration for 12 months.…”

Section: Long-term Studiesmentioning

confidence: 99%

The Role of Brassica Bioactives on Human Health: Are We Studying It the Right Way?

Quirante-Moya¹,

García-Ibáñez

Quirante-Moya

et al. 2020

Molecules

View full text Add to dashboard Cite

Brassica vegetables and their components, the glucosinolates, have been suggested as good candidates as dietary coadjutants to improve health in non-communicable diseases (NCDs). Different preclinical and clinical studies have been performed in the last decade; however, some concerns have been posed on the lack of established and standardized protocols. The different concentration of bioactive compounds used, time of intervention or sample size, and the lack of blinding are some factors that may influence the studies’ outcomes. This review aims to analyze the critical points of the studies performed with Brassica-related biomolecules and propose some bases for future trials in order to avoid biases.

show abstract

“…Ovarian cancer is the most common malignant gynecological cancer and the fifth leading cause of female cancer‐related health problems and deaths all over the world . Maximal cytoreductive surgery followed by platinum‐taxane chemotherapy has been the standard first‐line therapy for ovarian cancer . However, about 80% of advanced ovarian cancers relapse with a more aggressive and drug‐resistant disease .…”

Section: Introductionmentioning

confidence: 99%

“…1 Maximal cytoreductive surgery followed by platinum-taxane chemotherapy has been the standard first-line therapy for ovarian cancer. 2 However, about 80% of advanced ovarian cancers relapse with a more aggressive and drugresistant disease. 3 As with most malignant solid tumors, the formation of large numbers of microvessels constitutes the basis for growth and metastasis of ovarian cancer tumors.…”

Section: Introductionmentioning

confidence: 99%

LncRNA DANCR promotes tumor growth and angiogenesis in ovarian cancer through direct targeting of miR‐145

Lin

Yang

et al. 2019

Molecular Carcinogenesis

View full text Add to dashboard Cite

Differentiation antagonizing non‐protein coding RNA (DANCR) is a newly identified oncogenic long noncoding RNA found in various cancers. However, the functional role of DANCR in tumor angiogenesis and the underlying mechanisms are still unclear. The expression of DANCR was determined in ovarian malignant tissues and cell lines. The functional role of DANCR in tumor angiogenesis was revealed by the following methods: CD31 staining of ovarian tumor tissues, matrigel‐plug assay tissues, HUVEC‐related tube formation assay, and invasion assay. Enzyme‐linked immunosorbent assay, Western blotting, luciferase assay, and rescue experiments were used to investigate the underlying mechanisms of DANCR‐regulating angiogenesis. DANCR was upregulated in ovarian malignant tissues and ovarian cancer cells. Knockdown of DANCR efficiently impaired ovarian tumor growth through inhibition of tumor angiogenesis. Furthermore, the conditional culture medium from DANCR‐knockdown ovarian cells significantly inhibited tube formation and invasion of HUVEC in vitro. Mechanistic investigation indicated that vascular endothelial growth factor A (VEGF‐A, VEGF) plays a crucial role during DANCR inhibition of tumor angiogenesis in ovarian cancer. Further results demonstrated that miR‐145 is the direct binding target of DANCR during regulation of VEGF expression and tumor angiogenesis in ovarian cancer cells. Collectively, DANCR plays a promotional role in tumor angiogenesis in ovarian cancer through regulation of miR‐145/VEGF axis. Therefore, DANCR may be a novel therapy target for ovarian cancer.

show abstract

A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study

Cited by 36 publications

References 74 publications

Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice

Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice

The Role of Brassica Bioactives on Human Health: Are We Studying It the Right Way?

LncRNA DANCR promotes tumor growth and angiogenesis in ovarian cancer through direct targeting of miR‐145

Contact Info

Product

Resources

About